• Of the 17 patients in the efficacy population, 1 patient had a confirmed CR and 14 patients had a confirmed partial response (PR)
• Objective response rate (ORR; CR+PR) was 88% across the two cohorts FIGURE 5. TIME TO ABSTRACT #194528
• Chemotherapy-induced toxicity to the bone marrow and immune system has significant acute and long-term consequences
• Hematopoietic stem and progenitor cells (HSPCs) proliferate through a CDK4/6-dependent mechanism to produce circulating blood cells
• Actively proliferating HSPCs are sensitive to the cytotoxic effects of chemotherapy, and myelosuppression is the most severe and dose-limiting toxicity of such agents
• While the depletion of committed hematopoietic progenitor cells (HPCs) is largely responsible for the acute toxicity of chemotherapy, damage and functional attrition (via forced proliferation) of hematopoietic stem cells (HSCs) contributes to late chemotherapy-induced myelotoxicity (i.e., bone marrow exhaustion)
• Trilaciclib (G1T28) is a highly potent and selective CDK4/6 inhibitor (CDK4/6i) in development to reduce chemotherapy-induced myelosuppression and preserve immune system function in patients with CDK4/6-independent cancers such as SCLC
• • Platinum (cisplatin or carboplatin) plus etoposide is the standard of care for extensive-stage SCLC • Platinum/etoposide results in significant myelosuppression [3] [4] [5] [6] [7] [8] (Grade 3/4 neutropenia 47-92%, leukopenia 8-66%, thrombocytopenia 10-46%, and anemia 7-34%), requiring growth factor support, transfusions, dose delays, dose reductions, and hospitalizations
• In one of the largest Phase III trials evaluating carboplatin and etoposide (n=455 in the carboplatin/etoposide arm), the objective response rate (ORR) was 52% (1 CR) and the clinical benefit rate (CBR) was 75%
